Erenumab
| Evidence Level: L4 | Predicted Indications: 1 |
Table of Contents
Erenumab: From Migraine Prevention to Migraine with Brainstem Aura
One-Sentence Summary
Erenumab (marketed as AIMOVIG) is a CGRP-receptor antibody used to prevent migraine. The TxGNN model predicts it may be effective for migraine with brainstem aura, a specific migraine subtype. Currently there are 0 registered clinical trials and 20 publications on the topic, but none studied brainstem aura patients as a distinct group, so this is best treated as a research question.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Migraine prevention (the license records contain no indication text, so this comes from general knowledge) |
| Predicted New Indication | Migraine with brainstem aura |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L4 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 4 listings (all under BLA761077, since erenumab is a biologic) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the input. From general knowledge, erenumab is a monoclonal antibody that blocks the CGRP receptor. CGRP signaling drives trigeminovascular activation, a pathway shared across migraine subtypes.
Brainstem aura is a subtype of migraine with aura. Its aura is thought to arise from cortical or brainstem spreading depolarization. Erenumab is already used for migraine prevention, so this prediction is a subtype-level extension, not a new disease area.
The very high TxGNN score most likely reflects erenumab’s established use in migraine in general, not any signal specific to brainstem aura. Two points support this reading:
- Two studies in the pack (PMIDs 34928306 and 41888647) look at migraine with aura or aura frequency in general.
- None of the cited studies analyzed brainstem aura patients as a separate group.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 34928306 | 2022 | RCT (secondary analysis) | JAMA Neurology | Assessed erenumab safety and efficacy in patients with and without aura, motivated by the higher vascular risk in migraine with aura |
| 30360965 | 2018 | RCT (phase 3b) | Lancet | Randomized, double-blind, placebo-controlled study of erenumab in episodic migraine after 2–4 failed preventives; assessed efficacy and tolerability |
| 37012858 | 2023 | Systematic review | Int Immunopharmacol | Reviewed erenumab efficacy in preventing episodic and chronic migraine (migraine overall) |
| 36942409 | 2023 | Post hoc pooled analysis | Headache | Assessed cardiovascular safety of erenumab by degree of CV risk, in patients with and without aura |
| 41888647 | 2026 | Prospective study (REFORM) | J Headache Pain | Tracked changes in aura frequency during and after erenumab treatment in adults with frequent, confirmed aura |
| 40275185 | 2025 | Cohort (biomarker) | J Headache Pain | Tested whether plasma suPAR, elevated in migraine with aura, is linked to erenumab response |
| 38850034 | 2024 | Mechanistic provocation study | Cephalalgia | Tested whether sildenafil can induce migraine attacks in patients pre-treated with erenumab, to probe the cAMP/cGMP pathways |
| 32867533 | 2021 | Mechanistic clinical study | Cephalalgia | Examined whether erenumab alters cerebral vasomotor reactivity and endothelial function (migraine without aura) |
| 35538414 | 2022 | Cohort (real-world) | J Headache Pain | 12-month retrospective study of safety, tolerability and adverse-event predictors |
| 35230406 | 2022 | News/commentary | JAMA | News summary of the JAMA Neurology aura analysis; no abstract available |
US Market Information
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| BLA761077 | AIMOVIG | Injection (2 listings) | Amgen Inc |
| BLA761077 | AIMOVIG | Injection, solution (2 listings) | Amgen Inc |
The license records contain no approved indication text.
Safety Considerations
- Vascular and ischemic risk: CGRP plays a protective vasodilatory role, so patients with aura subtypes, who already have elevated vascular risk, need specific attention. PMIDs 36942409 and 32867533 address vascular effects, but only in general migraine populations, not brainstem aura.
Please refer to the package insert for warnings, contraindications and drug interactions.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is biologically plausible, since erenumab is already used for migraine prevention. However, there are no registered trials and no study has analyzed brainstem aura patients as a distinct group. The high model score most likely reflects migraine in general, and vascular risk in aura subtypes is unresolved.
To proceed, the following is needed:
- Package insert warnings and contraindications, downloaded from the FDA website
- Mechanism-of-action data from DrugBank
- A subgroup analysis of existing erenumab trial data, or a new study, focused on brainstem aura patients
- A vascular and ischemic safety assessment specific to aura subtypes
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.